Conference Coverage

SSRI tied to improved cognition in comorbid depression, dementia


 

FROM CTAD 2022

Small trial, open-label design

In a comment, Claire Sexton, DPhil, senior director of scientific programs and outreach at the Alzheimer’s Association, said the study “reflects a valuable aspect of treatment research because of the close connection between depression and dementia. Depression is a known risk factor for dementia, including Alzheimer’s disease, and those who have dementia may experience depression.”

senior director of scientific programs and outreach at the Alzheimer’s Association Alzheimer’s Association

Dr. Claire Sexton

She cautioned, however, that the trial was small and had an open-label design instead of the “gold standard” of a double-blinded trial with a control group.

The study was funded by Lundbeck, where Dr. Christensen is an employee. Another author is a Lundbeck employee, and a third author reported various disclosures. Dr. Sexton reported no disclosures.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Self-worth training boosts ketamine’s effects in severe depression
MDedge Internal Medicine
Preexisting mental illness symptoms spiked during pandemic
MDedge Internal Medicine
Study finds systemic AD treatment relieves depressive symptoms along with skin symptoms
MDedge Internal Medicine
Healthy diet, less news helped prevent anxiety, depression during COVID
MDedge Internal Medicine
Sexual assault–related visits to the ED are on the rise
MDedge Internal Medicine
Major depression treatments boost brain connectivity
MDedge Internal Medicine
The danger when doctors don’t get mental health help
MDedge Internal Medicine
Study finds high rate of psychiatric burden in cosmetic dermatology patients
MDedge Internal Medicine
Strong two-way link between epilepsy and depression
MDedge Internal Medicine
Mood stabilizers, particularly lithium, potential lifesavers in bipolar disorder
MDedge Internal Medicine